Clinical trial
SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the…
NCT00006351 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00006351 |
|---|---|
| Title | SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract |
| Official title | Phase II Study on SCH 66336 (Farnesyl Protein Transferase Inhibitor) and Gemcitabine as Second Line Treatment in Advanced Metastatic Urothelial Cancer - EORTC Study 16997 |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, lonafarnib |
| Enrollment | 34 |
| Start date | Jun 1, 2000 |
| Primary completion | Dec 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 24, 2012 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: